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In this issue of the Journal, Kumar and associates1 raise a number ofimportant points related to the clinical use of mitral homografts. Theirrather negative results obtained with antibiotic-preserved mitral homograftsneed to be carefully analyzed before discarding this operation which, in myopinion, could be a useful surgical alternative for the treatment of aparticular subset of patients in whom repair is not possible. At present, no
satisfactory substitute for mitral valve replacement exists. The morbidity of pros-
theses is higher in the mitral than in the aortic position: thromboembolic and
hemorrhagic complications in the case of mechanical prostheses and early degen-
eration in the case of bioprostheses. Furthermore, exclusion of the mitral valve
apparatus results in changes of left ventricular geometry and impairment of left
ventricular function. Thus, replacement of the mitral valve with a homograft offers
an attractive alternative because it would avoid the need for permanent anticoagu-
lation, maintain physiologic flow characteristics, and retain normal annulopapillary
continuity. Nevertheless, to date the use of mitral homografts has been restricted to
few centers; the difficulty of implantation remains the main obstacle to their use.
My colleagues and I have been using homograft mitral valve techniques since
1992,2 and our experience encompasses 102 patients. The operative technique
included the following characteristics: (1) partial or total replacement according to
the extent of the lesions, (2) fixation of the donor papillary muscle side to side to the
recipient’s papillary muscle with separated non–pledget-supported sutures, and (3)
systematic use of a prosthetic ring to compensate for imperfections.
Implantation of a mitral homograft is a complex procedure necessitating good
exposure of the subvalvular mitral apparatus. Occasionally, anatomic findings such
as severe left ventricular hypertrophy or nondilated and noncompliant left atrium,
which reduce visibility of the mitral valve, cannot be circumvented, making the
procedure technically impossible. Partial homograft replacement has been limited
and, in our most recent experience, complete homografts were generally used.3
Due to the variable and unpredictable morphology of the papillary muscles, their
fixation can be easy and reproducible when the papillary muscles have a single and
narrow head or difficult when bulky or divided into multiple heads. We have been
pleased that there has been no instance of postoperative papillary muscle dehis-
cence. Inspection of the papillary muscles at reoperation revealed a remarkable
anatomic appearance and excellent healing of the suture line with endothelialization
and fibrosis.
Since the beginning of our experience, an annuloplasty ring has been systemat-
ically inserted at the end of the procedure. The use of a slightly undersized ring
allows us to compensate for the unavoidable asymmetries in valvular geometry and
to adapt the size of the mitral orifice to the size of the homograft. In addition, the
use of a prosthetic ring provides an increased surface for leaflet coaptation, thereby
releasing the tension on the papillary muscle suture line. In this regard, it is
interesting to observe that the incidence of papillary muscle dehiscence was higher
in the report by Kumar and associates, in which an annuloplasty was performed in
only half of the cases.
As expected, a prosthetic ring reduces the mitral area: the functional area was
measured at 2 to 3 cm2 in our series3 as compared with 3 to 4 cm2 in Kumar’s series.
It can be concluded that the addition of a prosthetic ring increases the reliability of
the procedure at the price of a mild reduction in orifice area.
In our experience, the main limitation of the mitral homograft has been the risk
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of valve dysfunction due to a severe mismatch at implan-
tation that could not be corrected with a prosthetic ring.
Ignoring or minimizing an unsatisfactory echocardiographic
result will lead to an early reoperation. This risk might
invalidate the indication for this operation in areas of the
world in which a second procedure cannot be economically
afforded by the patient.
At present, it is difficult to assess the long-term outcome
of mitral homografts due to the bias introduced by early
valve dysfunction. In our experience, normal valve function
was present in 80% of the cases at a 41-month follow-up
period. Reoperation should be imputed to structural deteri-
oration only in those patients whose initial result was fully
satisfactory. In our series, degeneration of the homograft
was identified in only 3 patients. It is widely known that the
type of homograft preservation influences the late outcome:
cryopreservation was used in our series, whereas Kumar’s
series included mainly antibiotic-preserved valves, which
may also account for the differences in results between the
two reports.
Seven years of experience with mitral homografts has
shown that (1) rheumatic etiology could be the prime indi-
cation for this technique, (2) the side-to-side technique of
papillary muscle implantation is reliable, and (3) the use of
a prosthetic ring is necessary to ensure satisfactory results.
However, we agree with Kumar and associates that, at
present, the mitral homograft is not yet a standardized
procedure to be undertaken routinely, does not assure suc-
cess in every case, and is not applicable to all mitral re-
placements. The mitral homograft still belongs to the field
of clinical research and its use should not be widespread but
limited to a few centers. An improvement in the method of
measuring the mitral valve is necessary so as to appropri-
ately select the homograft.
Despite possible refinements in the future, the operation
will certainly remain challenging. If one day the technical
difficulties can be circumvented, as for aortic homografts,
durable results can be expected. Whether this experience
should be continued is answered by the absence of a satis-
factory mitral prosthesis.
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